313 related articles for article (PubMed ID: 17235306)
1. mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft.
Inoue S; Hartman A; Branch CD; Bucana CD; Bekele BN; Stephens LC; Chada S; Ramesh R
Mol Ther; 2007 Feb; 15(2):287-94. PubMed ID: 17235306
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated mda-7 (IL24) gene therapy suppresses angiogenesis and sensitizes NSCLC xenograft tumors to radiation.
Nishikawa T; Ramesh R; Munshi A; Chada S; Meyn RE
Mol Ther; 2004 Jun; 9(6):818-28. PubMed ID: 15194048
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial synergy induced by adenoviral-mediated mda-7 and Herceptin in Her-2+ breast cancer cells.
Bocangel D; Zheng M; Mhashilkar A; Liu Y; Ramesh R; Hunt KK; Chada S
Cancer Gene Ther; 2006 Oct; 13(10):958-68. PubMed ID: 16783343
[TBL] [Abstract][Full Text] [Related]
4. Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer.
Oida Y; Gopalan B; Miyahara R; Inoue S; Branch CD; Mhashilkar AM; Lin E; Bekele BN; Roth JA; Chada S; Ramesh R
Mol Cancer Ther; 2005 Feb; 4(2):291-304. PubMed ID: 15713900
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells.
McKenzie T; Liu Y; Fanale M; Swisher SG; Chada S; Hunt KK
Surgery; 2004 Aug; 136(2):437-42. PubMed ID: 15300212
[TBL] [Abstract][Full Text] [Related]
6. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer.
Anai S; Sakamoto N; Sakai Y; Tanaka M; Porvasnik S; Urbanek C; Cao W; Goodison S; Rosser CJ
Urol Oncol; 2011; 29(4):421-9. PubMed ID: 19576799
[TBL] [Abstract][Full Text] [Related]
7. Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice.
Yagi Y; Fushida S; Harada S; Tsukada T; Kinoshita J; Oyama K; Fujita H; Ninomiya I; Fujimura T; Kayahara M; Kinuya S; Yashiro M; Hirakawa K; Ohta T
Cancer Chemother Pharmacol; 2010 Sep; 66(4):745-53. PubMed ID: 20033809
[TBL] [Abstract][Full Text] [Related]
8. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
9. Erlotinib and bevacizumab have synergistic activity against melanoma.
Schicher N; Paulitschke V; Swoboda A; Kunstfeld R; Loewe R; Pilarski P; Pehamberger H; Hoeller C
Clin Cancer Res; 2009 May; 15(10):3495-502. PubMed ID: 19447871
[TBL] [Abstract][Full Text] [Related]
10. MDA-7/IL-24 suppresses human ovarian carcinoma growth in vitro and in vivo.
Gopalan B; Shanker M; Chada S; Ramesh R
Mol Cancer; 2007 Feb; 6():11. PubMed ID: 17274815
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of nuclear factor-kappaB augments antitumor activity of adenovirus-mediated melanoma differentiation-associated gene-7 against lung cancer cells via mitogen-activated protein kinase kinase kinase 1 activation.
Oida Y; Gopalan B; Miyahara R; Branch CD; Chiao P; Chada S; Ramesh R
Mol Cancer Ther; 2007 Apr; 6(4):1440-9. PubMed ID: 17431123
[TBL] [Abstract][Full Text] [Related]
12. A novel synergistic effect of iron depletion on antiangiogenic cancer therapy.
Ohara T; Noma K; Urano S; Watanabe S; Nishitani S; Tomono Y; Kimura F; Kagawa S; Shirakawa Y; Fujiwara T
Int J Cancer; 2013 Jun; 132(11):2705-13. PubMed ID: 23161652
[TBL] [Abstract][Full Text] [Related]
13. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
[TBL] [Abstract][Full Text] [Related]
15. A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment.
Zhang H; Yun S; Batuwangala TD; Steward M; Holmes SD; Pan L; Tighiouart M; Shin HJ; Koenig L; Park W; Rycroft D; Nannapaneni S; Wang Y; Chen ZG; Shin DM
Int J Cancer; 2012 Aug; 131(4):956-69. PubMed ID: 21918971
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo.
Saeki T; Mhashilkar A; Swanson X; Zou-Yang XH; Sieger K; Kawabe S; Branch CD; Zumstein L; Meyn RE; Roth JA; Chada S; Ramesh R
Oncogene; 2002 Jul; 21(29):4558-66. PubMed ID: 12085234
[TBL] [Abstract][Full Text] [Related]
17. Genetic delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice.
Watanabe M; Boyer JL; Hackett NR; Qiu J; Crystal RG
Hum Gene Ther; 2008 Mar; 19(3):300-10. PubMed ID: 18324912
[TBL] [Abstract][Full Text] [Related]
18. Effect of yeast-derived beta-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models.
Zhong W; Hansen R; Li B; Cai Y; Salvador C; Moore GD; Yan J
J Immunother; 2009 Sep; 32(7):703-12. PubMed ID: 19561538
[TBL] [Abstract][Full Text] [Related]
19. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
20. Melanoma differentiation-associated gene-7 (mda-7)/interleukin (IL)-24 induces anticancer immunity in a syngeneic murine model.
Miyahara R; Banerjee S; Kawano K; Efferson C; Tsuda N; Miyahara Y; Ioannides CG; Chada S; Ramesh R
Cancer Gene Ther; 2006 Aug; 13(8):753-61. PubMed ID: 16543916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
